Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9312MR)

This product GTTS-WQ9312MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9312MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15826MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ8066MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ8142MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ9355MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ12795MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ10254MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ3870MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ5687MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW